Monitoring of benzodiazepine diversion using a multi-indicator approach

International Clinical Psychopharmacology

Volumn 26, Issue 5, 2011, Pages 268-277

  Pauly, Vanessa ^a   Frauger, Elisabeth ^b,c   Pradel, Vincent ^b,c   Nordmann, Sandra ^b,c   Pourcel, Laure ^c   Natali, Francois ^e   Sciortino, Vincent ^e   Lapeyre Mestre, Maryse ^d   Micallef, Joelle ^b,c   Thirion, Xavier ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c AIX MARSEILLE UNIVERSITÉ   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e Direction Regionale du Service Medical de la Region Provence Alpes Cote d'Azur et Corse   (France)

Author keywords

benzodiazepines; drug reimbursement database; postmarketing surveillance; prescription drug abuse; substance related disorder

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; FLUNITRAZEPAM; ILLICIT DRUG; LORAZEPAM; LORMETAZEPAM; NORDAZEPAM; OXAZEPAM; PRAZEPAM; PRESCRIPTION DRUG; TETRAZEPAM; ZOLPIDEM; ZOPICLONE;

ARTICLE; DRUG ABUSE; DRUG MARKETING; MONITORING; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; REIMBURSEMENT;

BENZODIAZEPINES; CLONAZEPAM; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DATABASES, FACTUAL; DIAZEPAM; FLUNITRAZEPAM; HUMANS; PRESCRIPTION DRUGS; PRINCIPAL COMPONENT ANALYSIS; SUBSTANCE-RELATED DISORDERS;

EID: 80051771435     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834967e5     Document Type: Article

References (59)

1. Barrau C, Thirion X, Micallef J, Chuniaud-Louche C, Bellemin B, San Marco JL (2001). Comparison of methadone and high dosage buprenorphine users in France? Addiction 96:1433-1441. (Pubitemid 32977082)
2. Boeuf O, Lapeyre-Mestre M (2007). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France. Drug Saf 30:265-276. (Pubitemid 46425637)
3. Brands B, Paglia-Boak A, Sproule BA, Leslie K, Adlaf EM (2010). Nonmedical use of opioid analgesics among Ontario students. Can Fam Physician 56:256-262.
4. Bunn TL, Yu L, Spiller H, Singleton M (2010). Surveillance of methadone-related poisonings in Kentucky using multiple data sources. Pharmacoepidemiol Drug Saf 19:124-131.
5. Butler S, Budman S, Licari A, Cassidy T, Lioy K, Dickinson J, et al. (2008). National addictions vigilance intervention and prevention program (NAVIPPRO): a realtime, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 17:1142-1154.
6. Centers for Disease Control and Prevention (CDC). (2010) Emergency department visits involving non medical use of selected prescription drugs - United States, 2004-2008 Morbidity and Mortality Weekly Report (MMWR).
7. CEWG. (2009). Epidemiologic trends in drug abuse. Proceedings of the community epidemiology work group, vol 1, June 2009 page 63 section II, table 1. Available at http://www.drugabuse.gov/PDF/CEWG/CEWGJan09508Compliant.pdf [Accessed 28 October 2010].
8. Cicero T, Dart C, Inciardi J, Woody E, Schnoll S (2007). The development of a comprehensive risk-management program. Pain Med 8:157-171.
9. Cicero TJ, Ellis M, Paradis A, Ortbal Z (2010). Determinants of fentanyl and other potent m opioid agonist misuse in opioid-dependent individuals. Pharmacoepidemiol Drug Saf 19:1057-1063.
10. Dart R (2009). Monitoring risk: post marketing surveillance and signal detection. Drug Alcohol Depend 105 S: S26-S32.
11. DAWN. Detailed tables: national estimates, drug-related emergency department visits for 2004-2008. http://dawninfo.samhsa.gov/data/default.asp? met=All [Accessed 24 June 2011].
12. Djezzar S, Questel F, Burin E, Dally S. French Network of Centers for Evaluation and Information on Pharmacodependence (2009). Chemical submission: results of 4-year French inquiry. Int J Legal Med 123:213-219.
13. Escot S, Fahet G. 2004 Usages non substitutifs de la buprenorphine haut dosage. Investigation menée en France, en 2002-2003. Observatoire Français des Drogues et Toxicomanies OFDT
14. Fishman S, Papazian J, Gonzalez S, Riches P, Gilson A (2004). Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Med 5:309-324. (Pubitemid 39369254)
15. Fourrier A, Letenneur L, Dartigues J, Moore N, Bégaud B (2001). Benzodiazepine use in an elderly community-dwelling population: characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol 57:419-425. (Pubitemid 33787193)
16. Foutain J, Strang J, Gossop M, Farrell M, Griffiths P (2000). Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 95:393-406. (Pubitemid 30167633)
17. Frauger E, Pradel V, Natali F, Thirion X, Reggio P, Micallef J (2006). Detournement d'usage du clonazepam (Rivotril): tendances recentes. Therapie 61:49-55. (Pubitemid 350213994)
18. Frauger E, Vigneau C, Orléans V, Thirion X, Jolliet P, Micallef J, et al (2008). Consumption of cannabis among subjects with history of abuse/dependence or under an opiate maintenance therapy: OPPIDUM data in 2006 and main trends since 2004. Therapie 63:119-127.
19. Frauger E, Pauly V, Thirion X, Natali F, Pradel V, Reggio P, et al (2009). Estimation of clonazepam abuse liability: a new method using a reimbursed drug database. Int Clinical Psychopharmacology 24:318-324.
20. Frauger E, Pauly V, Pradel V, Rouby R, Arditti J, Thirion X, et al (2010). Evidence of clonazepam abuse liability: results of the tools developed by the French centers for evaluation and information on pharmacodependence (CEIP) network. Fundam Clin Pharmacol (in press). doi: 10.1111/j.1472-8206.2010. 00882.x
21. Gelkopf M, Bleich A, Hayward R, Bodner G, Adelson M (1999). Characteristics of benzodiazepin abuse in Methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend 55:63-68. (Pubitemid 29222004)
22. Gerada C, Ashworth M (1997). ABC of mental health: addiction and dependence I: illicit drugs. BMJ 315:297-300. (Pubitemid 27326215)
23. Griffiths R, Johnson M (2005). Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66:31-41. (Pubitemid 43011561)
24. Hando J, Darke S, O'Brien S, Maher L, Hall WD (1998). The development of an early warning system to detect trends in illicit drug use in Australia: the illicit drug reporting system. Addict Res Theory 6:97-113.
25. IDRSA [Online] The illicit Drug Reporting System in Australia. http://www.med.unsw.edu.au/ndarcweb.nsf/page/IDRSa [Accessed 28 October 2010].
26. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2009). Monitoring the future national results on adolescent drug use: overview of key findings, 2008 (NIH Publication No. 09-7401). Bethesda, MD: National Institute on Drug Abuse.
27. Kessler D (1993). Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 269:2765-2768. (Pubitemid 23154251)
28. Lagnaoui R, Depont F, Fourrier A, Abouelfath A, Bégaud B, Verdoux H, Moore N (2004). Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 60:523-529. (Pubitemid 39350165)
29. Lapeyre-Mestre M, Llau ME, Gony M, Navel A-M, Bezc J, Grau M, et al (2003). Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users. Drug Alcohol Depend 72:297-303. (Pubitemid 37485907)
30. Llau ME, Lapeyre-Mestre M, Plas L, Damase-Michel C, Montastruc JL (2002). Forged medical prescriptions in a community pharmacy network in Midi-Pyrenees area: assessment of a falsification ratio. Eur J Clin Pharmacol 57:911-912. (Pubitemid 34185563)
31. Mac Carthy M (2007). Prescription drug abuse up sharply in the USA. Lancet 369:1505-1506.
32. Manchikanti L (2006). Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the subcommittee on criminal justice, drug policy and human resources. Pain Physician 9:287-321. (Pubitemid 44717789)
33. Manchikanti L (2007). National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 10:399-424. (Pubitemid 46971294)
34. Manchikanti L, Singh A (2008). Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 11:S63-S88. (Pubitemid 351682079)
35. Manchikanti L, Brown KR, Singh V (2002). National all schedules prescription electronic reporting act (NASPER): balancing substance abuse and medical necessity. Pain Physician 5:294-319.
36. Martin-Latry K, Bégaud B (2010). Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 19:256-265.
37. McCabe SE, Boyd CJ, Teter CJ (2009). Subtypes of nonmedical prescription drug misuse. Drug Alcohol Depend 102:63-70.
38. Micallef J, Pradel V, Thirion X, Jolliet P, Lapeyre-Mestre M (2004). Use of the health insurance database by the centres for evaluation and information on pharmacodependance: examples, interests and future prospects. Therapie 59:581-588. (Pubitemid 40353959)
39. Mintzer MZ, Griffiths RR (2005). An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. Behav Pharmacol 16:579-584. (Pubitemid 41416077)
40. Medicam Database. 2004-2009. CNAMTS - Direction Délé guée à la Gestion et à l'Organisation des Soins (DDGOS), Département des Produits de Santé. http://www.mypharma-editions. com/medicam
41. Modelon H, Frauger E, Laurenceau D, Thirion X, Mallaret M, Micallef Jet le réseau des CEIP4. Abus et dépendances aux produits psychoactifs: étude de consommations à travers l'enquête OPPIDUM 2004 du réseau des CEIP. Therapie 2007;62:337-346. (Pubitemid 351211749)
42. Mounteney J, Haugland S (2009). Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines. Int J Drug Policy 20:161-169.
43. National Institute on Drug Abuse 2010 Prescription drugs abuse and addiction. http://www.drugabuse.gov/pdf/tib/prescription.pdf [Accessed 25 January 2010].
44. NFLIS. 2009 Proceedings of the community epidemiology Work group, vol 1, June 2009 page 63 section II, table 1.
45. Office of Applied Studies (OAS). 2005 Results from the 2004 National Survey on Drug Use and Health: National findings (DHHS Publication No. SMA 05-4062, NSDUH Series H-28). Rockville, MD: Substance Abuse and Mental Health Services Administration. http://www.oas.samhsa.gov/nsduh/reports.html
46. Office of Applied Studies (OAS). 2007 Drug Abuse Warning Network, 2007: National estimates of drug-related emergency department visits. https://dawninfo.samhsa.gov/files/ED2007/DAWN2k7ED.pdf [Accessed 28 October 2010].
47. Pauly V, Frauger E, Pradel V, Rouby F, Berbis J, Natali F, et al (2011). Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling high dosage buprenorphine abuse. Drug Alcohol Depend 113:29-36.
48. Pradel V, Thirion X, Ronfle E, Masut A, Micallef J, Bégaud B (2004). Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol Drug Saf 13:481.
49. Pradel V, Frauger E, Thirion X, Ronfle E, Lapierre V, Masut V, et al (2009). Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf 18:43.
50. Pradel V, Delga C, Rouby F, Micallef J, Lapeyre-Mestre M (2010). Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator. CNS Drugs 24:611-620.
51. Rigg K, Ibanez G (2010). Motivations for non-medical prescription drug use. J Subst Abuse Treat 39:236-247.
52. Schneider M, Bailey E, Cicero T, Dart R, Inciardi J, Parrino M, et al (2009). Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007. Pharmacoepidemiol Drug Saf 18:778-798.
53. Steentoft A, Linnet K (2009). Blood concentrations of clonazepam and 7-aminoclonazepam in forensic cases in Denmark for the period 2002-2007. Forensic Sci Int 184:74-79.
54. Thirion X, Micallef J, Barrau K, Djezzar S, SanMarco JL, Lagier JL (2001). Observation of psychoactive substance consumption: methods and results of the French OPPIDUM Programme. Addict Res 7:32-36. (Pubitemid 32337197)
55. Thirion X, Lapierre V, Micallef J, Ronfle E, Masut A, Pradel V, et al (2002). Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 65:197-204. (Pubitemid 34084903)
56. Tracqui A, Kintz P, Ludes B (1998). Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 22:430-434. (Pubitemid 28457815)
57. Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P (2007). Evidence of zolpidem abuse and dependence: results of the French centre for evaluation and information on pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 64:198-209. (Pubitemid 47063241)
58. Ward JH (1963). Hierarchical grouping to optimize an objective function. J Am Statist Assoc 58:236-244.
59. WHO Collaborating Center For Drug Statistics Methodology. 2010 Guidelines for ATC classification and DDD Assignment, 2010. Oslo, Norway. http://www.whocc.no/atcddd/[Accessed 28 October 2010].